Home  |  Contact Us  |  Site Map

Investor Relations

Corporate Profile
Prometheus Laboratories Inc. is a specialty pharmaceutical company committed to developing new ways to help physicians individualize patient care. Prometheus focuses on the treatment, diagnosis and detection of gastrointestinal, autoimmune and inflammatory diseases and disorders. Prometheus’ strategy includes the marketing and delivery of pharmaceutical products complemented by its proprietary, high-value diagnostic testing services. By integrating therapeutics and diagnostic services, Prometheus addresses the continuum of patient care, thereby providing physicians with a comprehensive solution to treat chronic diseases.
Recent NewsMore >>>
10/10/13Printer Friendly VersionPrometheus Laboratories Inc. Announces Inclusion of Proleukin® (Aldesleukin for Injection) / Interleukin 2 in SITC Guidelines for Treatment of Cutaneous Melanoma
09/19/13Printer Friendly VersionPrometheus Laboratories Appoints Chief Executive Officer
05/30/13Printer Friendly VersionPrometheus Laboratories Launches PROCLIVITY 02, a Phase IV Multi-Center Study Comparing the Sequence of Proleukin® (Aldesleukin for Injection) and Yervoy® (Ipilimumab) in Patients with Metastatic Melanoma
Conference Presentations
There are currently no events scheduled.

Home  |   Contact Us  |   Site Map  |   Privacy Policy  |   Legal Notices   |   ProNet